Cancer Gene Therapy

FIGURE 2

FROM:

A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma

Alok A Khorana, J D Rosenblatt, D M Sahasrabudhe, T Evans, M Ladrigan, D Marquis, K Rosell, T Whiteside, S Phillippe, B Acres, P Slos, P Squiban, M Ross and K Kendra

BACK TO ARTICLE

Figure 2.

Figure and tables index
Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Serum IL-6 levels at different time points for patients 006 (cycles 1 and 2), 007 and 011. A significant increase in serum IL-6 levels was seen in patient 006 (cycle 1) and in patient 011, both at 6 hours postinjection on day 15. Patients 006 (cycle 2) and 007 are representative of other patients who did not manifest such an increase.

Figure and tables index
BACK TO ARTICLE